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Abstract
Despite exhibiting oncogenic events, patient’s leukemia cells are responsive and dependent on signals from their malignant
bone marrow (BM) microenvironment, which modulate their survival, cell cycle progression, trafficking and resistance to
chemotherapy. Identification of the signaling pathways mediating this leukemia/microenvironment interplay is critical for
the development of novel molecular targeted therapies.
We observed that primary leukemia B-cell precursors aberrantly express receptors of the BAFF-system, BAFF-R, BCMA, and
TACI. These receptors are functional as their ligation triggers activation of NF-kB, MAPK/JNK, and Akt signaling. Leukemia
cells express surface BAFF and APRIL ligands, and soluble BAFF is significantly higher in leukemia patients in comparison to
age-matched controls. Interestingly, leukemia cells also express surface APRIL, which seems to be encoded by APRIL-d,a
novel isoform that lacks the furin convertase domain. Importantly, we observed BM microenvironmental cells express the
ligands BAFF and APRIL, including surface and secreted BAFF by BM endothelial cells. Functional studies showed that
signals through BAFF-system receptors impact the survival and basal proliferation of leukemia B-cell precursors, and support
the involvement of both homotypic and heterotypic mechanisms.
This study shows an unforeseen role for the BAFF-system in the biology of precursor B-cell leukemia, and suggests that the
target disruption of BAFF signals may constitute a valid strategy for the treatment of this cancer.
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Introduction
Increasing evidence indicates that microenvironmental cues play
criticalroles in cancer biologyand that malignant cells are responsive to
multiple extrinsic factors from their microenvironment. These stimuli
involve both soluble factors and receptor/ligand interactions, which
mediate or influence processes as tumor development, maintenance,
drug-resistance and immune evasion.[1] Studies indicate that the
‘leukemia microenvironment’ supports acute lymphoblastic leukemia
(ALL) cells developing in the bone marrow (BM), namely by providing
survival/proliferation signals and by functioning as potential niches for
chemotherapy-resistant tumor cells.[2,3,4,5,6]
Ligands and receptors of the tumor-necrosis factor (TNF)
superfamily play significant roles in B-cell development and
homeostasis. B-cell-activating factor (BAFF; BLyS)[7] is a TNF-
superfamily member expressed by various cell types [reviewed [8]],
and has been shown to prolong B-cell survival.[9,10] BAFF
transgenic mice exhibit increased number of B-cells, expressing
elevated levels of anti-apoptotic molecules.[11,12] In addition to
serving asa potent B-cellsurvival factor,[8] BAFFalsofunctionsas a
costimulator of B-cell proliferation.[7,13] BAFF shares significant
homology with APRIL (a proliferation-inducing ligand).[8,14]
Three known receptors for BAFF 2 BCMA (B-cell maturation
antigen),[15,16] TACI (transmembrane activator, calcium-modu-
lator, cyclophilin ligand interactor)[16,17] and BAFF-R (BAFF-
receptor) have been identified, which are expressed by immature/
mature B-lymphocytes.[18,19,20,21] BCMA and TACI also bind
APRIL, whereas BAFF-R exclusively interacts with BAFF. The
role of BCMA in B-cell homeostasis remains undefined: whereas
injection of BCMA-Ig, as decoy receptor, resulted in marked B-cell
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mice did not exhibit an obvious phenotype.[22,23] TACI-null
mice showed elevated B-cell numbers, suggesting a negative
regulatory role for TACI on B-cell homeostasis;[24,25] TACI-Ig
administration also led to inhibition of T-cell-independent
immune responses,[26] abolition of germinal center formation[27]
and prolonged B-cell lifespan.[17] The phenotype of BAFF-R-
deficient mice is similar to that of BAFF-deficient mice, with
impaired B-cell maturation beyond the T1 stage, decreased Ig
levels and decreased T-cell-dependent and T-cell-independent
immune responses.[20,21,28] This suggests that the BAFF/BAFF-
R axis is the main driver for B-cell survival and matura-
tion.[20,21,28].
The mechanisms regulating BAFF-system molecule expression
are poorly understood. Interleukin-10, Interferon-a (IFN-a), IFN-c
and CD154/CD40L can upregulate BAFF or APRIL expression
in different cells, including macrophages/monocytes and dendritic
cells.[29,30] During malignant transformation, cells undergo
genetic/epigenetic alterations that drive changes in their pro-
teome, such as over-expression or aberrant expression of critical
molecules. APRIL, which is expressed at low levels by normal
cells,[29,30] is upregulated on B-cell chronic lymphocytic
leukemia (CLL), lymphoma and myeloma cells ([14], reviewed
in [31]), i.e. malignancies involving late-stage B-cells. BAFF is
expressed by malignant mature B-cells,[31] in contrast to their
normal counterparts.[7] Both ligands have been implicated in
proliferation and survival of malignant B-cells.[31]
The pattern of BAFF-system receptor expression during B-cell
development[28] suggests that BAFF/APRIL lack functional roles
in early stage B-cells. Fittingly, BAFF transgenic mice exhibited
normalcelldistributions and differentiation ofprecursor/progenitor
B-lineage cells.[11,12,17] Here, we show that primary leukemia B-
cell precursor ALL (B-ALL) express functional receptors of the
BAFF-system, particularly BAFF-R, and that their stimulation by
BAFF potentiates cell proliferation and results in the engagement of
survival pathways. Moreover, we show that BAFF and APRIL are
expressed by cells of the BM microenvironment known to support
leukemia, as well as by the leukemia cells themselves. These studies
indicate that BAFF-system ligands function through both homo-
typic and heterotypic mechanisms on leukemia B-cells, revealing a
new role for the BAFF-system in B-ALL biology.
Results
Leukemia B-cell Precursors Express BAFF-R, BCMA, and
TACI Receptors
Little is known on the key microenvironmental factors involved in
the biology of B-cell precursor ALL (hereafter referred as B-ALL;
includes leukemias of pro-B, pre-B and immature B-cells). As part of a
screening assessing the putative involvement of TNF-superfamily
members on B-ALL, we assessed the expression of BCMA, TACI and
BAFF-R in primary leukemia B-cell precursors (patients’ characteris-
tics in Table S1). PCR analyses of full-length mRNAs were performed
in primary B-ALL cells (BM or PB; n=36) and B-ALL lines (n=6).
BAFF-R and TACI transcripts were detected in all B-ALL lines,
whereasBCMA was detected in 4of them; theirrelative expressionwas
stronger in pre-B-cell (207, SUP-B15, BLIN-1, NALM-6) than in pro-
B-cell lines (REH, RS4;11; Figure 1A). Analysis of primary B-ALL
specimens showed that BCMA and BAFF-R transcripts are present in
all cases tested, with TACI mRNA detected in 35 patients (Figure 1A;
data not shown). No differences were observed between BM and PB
specimens from the same patient (n=6; data not shown). Nucleotide
sequencing confirmed that the transcripts amplified corresponded to
the respective genes, and no mutations were detected (n=12 patients;
data not shown). BCMA, TACI and BAFF-R transcripts were observed
also in normal B-cell precursor (BCP; containing pro-/pre-B and
immature B-cells; n=4) specimens from age-matched healthy donors
(Figure 1A; data not shown).
Receptor expression was analyzed at a single cell level by flow
cytometryinprimaryB-ALL(n=23),B-ALLlines(n=6)andnormal
BCP (n=4)samples.SurfaceformsofBAFFreceptors(Figure1B,left
and central panels for representative cases) were detected in B-ALL
primary cells and cell lines. For the latter, BAFF-R was the receptor
mostcommonlyexpressed whereas BCMA and TACI were generally
low or absent (Figure 1C, left panel). As shown in Figures 1B and 1C
(right panel), all B-ALL patients express BAFF-R (mean 51.46%,
range 5.09–96.5%), TACI (mean 33.15%, range 0.11–97.7%),
whereas BCMA was seen in some patients (mean 26.56%; range
1.28–96.7%). Individual analyses revealed that all B-ALL patients
tested expressed at least one of these receptors (data not shown).
Importantly, BAFF-system receptors are absent or weakly expressed
on normal BCP (Figure 1B; BCMA, mean 1.15%, range 0.39–
1.75%; TACI, mean 3.24%, range 0.05–7.9%; BAFF-R, mean
2.05%, range 0.07–4.9%).This is in accordance with reported studies
showing that the expression of these receptors is restricted to more
differentiated stages of B-cell lineage development.[18,19,20] The
presence of mRNA transcripts (Figure 1A, right panel) but not surface
receptors in normal BCP suggests their regulation via post-
transcriptional mechanism(s) during normal B-cell development.
B-ALL Cells Express BAFF and APRIL
We analyzed leukemia B-cells for expression of BAFF and
APRIL. Most B-ALL lines (5 of 6) and primary B-ALL specimens
(35 of 36) expressed BAFF transcripts, with variable intensity
(Figure 2A; data not shown). No differences were observed between
BM and PB specimens from the same patient (n=6; data not
shown). Nucleotide sequencing confirmed that the amplified
product corresponded to BAFF (n=3 patients; data not shown).
APRIL mRNA was detected in all primary B-ALL and in most cell
lines (5 of 6), with the presence of distinct transcripts, corresponding
to isoforms -a, -b and -c (Figure 2A), as confirmed by nucleotide
sequencing. Interestingly, 35 of 36 primary B-ALL also exhibited an
additional band, which nucleotide sequencing (n=11) revealed as a
novel APRIL isoform, APRIL-d (reported to GenBank as accession
number DQ149579) that results from an alternative-splicing event
where exon 2 is missing, thus lacking the furin convertase motif
RKRR [32] (Figure 2B; Figure S1). BAFF and APRIL transcripts
were observed also in normal BCP (n=4) specimens from age-
matched healthy donors (Figure 2A; data not shown).
Analyses of surface expression of BAFF and APRIL on B-ALL
primary cells (n=23), cell lines (n=6), and normal BCP (n=4),
showed that both ligands are expressed by malignant cells
(Figure 2C, left and central panels for representative cases). All
primary precursor B-ALL cases express BAFF, with a mean
expression of 67.8% (Figure 2D; range 15.5–98.6%) and most
express APRIL (Figure 2D; mean 54.03%, range 1.94–98.5%).
Individual analyses revealed that cells from 22 out of 23 B-ALL
patients expressed both BAFF and APRIL on their surface (data
not shown). This finding was unexpected since membrane-bound
APRIL is efficiently processed into its soluble form.[8,32] Since the
novel isoform APRIL-d lacks the consensus motif required for
furin convertase-mediated cleavage (Figure 2B) and contains a
transmembrane-like domain, it is possible that the APRIL detected
on the cell surface of B-ALL cells represents this isoform. As seen
with BAFF-system receptors, the expression of the ligands was also
almost undetectable on normal BCP (Figure 2C right panel for
representative cases; BAFF, mean 1.42%, range 0.03–2.94%;
APRIL, mean 2.59%, range 0.07–5.33%).
BAFF-System in B-Cell ALL
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20787Finally, the presence of soluble BAFF in the leukemia
milieu was assessed by ELISA in the plasma of B-ALL pa-
tients (n=39) and compared to the plasma of age-matched
controls (n=21). Mean levels of soluble BAFF are significantly
higher in B-ALL patients in comparison to control specimens
(Figure 2E; p=0.0006; B-ALL, mean 17.68 ng/mL, range
2.4–130.0 ng/mL; controls, mean 4.81 ng/mL, range 1.0–
18.0 ng/mL).
Figure 1. Primary B-ALL express BAFF-system receptors. (A) Electrophoretic analysis of RT-PCR products of BCMA, TACI and BAFF-R in B-ALL
lines (left), primary B-ALL (center) and BCP from normal donors (right). Splenic mature B-cells as positive control (+); PBGD as control transcript. (B)
Flow cytometry of surface BCMA, TACI and BAFF-R on representative B-ALL lines, B-ALL patients and normal BCP. (C) Summary of surface BCMA (&),
TACI (.) and BAFF-R (N) expression (% of cells) in B-ALL patients (n=23; BCMA+TACI+BAFF-R, 17/23; BCMA+BAFF-R 2/23; TACI+BAFF-R 3/23; only
BAFF-R, 1/23; only TACI or BCMA, or BCMA+TACI, 0/23) and lines (n=6) evaluated by flow cytometry; solid line indicates mean surface expression (%
of cells). B-ALL lines: BCMA, mean 2.23%, range 0.6–5.54%; TACI, mean 11.67%, range 1.51–27.2%; BAFF-R, mean 45.96%, range 3.07–99.5%.
doi:10.1371/journal.pone.0020787.g001
BAFF-System in B-Cell ALL
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20787Figure 2. Primary B-ALL express BAFF and APRIL. (A) Electrophoretic analysis of RT-PCR products of BAFF and APRIL in B-ALL lines (left), primary
B-ALL (center) and normal BCP (right). Monocytes as positive control (+); PBGD as control transcript. A 940bp band was identified as the new isoform
APRIL-d. (B) Comparison of aminoacid sequences of APRIL-a and the predicted for APRIL-d, which results from alternative splicing with exon-1/exon-3
fusion (lacking residues as dashed lines); this results in a 104 predicted aminoacid protein lacking the motif for furin convertase (in bold). (C) Flow
cytometry of BAFF, APRIL expression on representative cases of B-ALL patients, B-ALL lines and normal BCP. (D) Summary of BAFF (m) and APRIL (¤)
surface expression in B-ALL patients (n=23; BAFF+APRIL, 22/23; only BAFF, 1/23; only APRIL, 0/23) or lines (n=6) evaluated by flow cytometry; solid
line indicates mean surface expression (% of cells). (E) ELISA for soluble BAFF in plasma from B-ALL patients (n=39) or age-matched controls (n=21);
solid lines indicate mean levels of BAFF for each group. Statistical analysis performed using Mann-Whitney test.
doi:10.1371/journal.pone.0020787.g002
BAFF-System in B-Cell ALL
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BM-stromal (BM-S) myofibroblasts support leukemia cell
functions[2,3] and tumor-stimulated BM endothelium (BM-EC)
promotes the survival of primary leukemia cells,[6] with BM
endothelial microdomains functioning as niches for leukemia cell
maintenance.[33] Since BAFF and APRIL can promote malig-
nant cell survival and proliferation in mature B-cell tumors
developing in the BM,[31] we investigated the expression of
BAFF-system transcripts in BM-EC (n=5), mesenchymal stem
cells (MSC; n=4) and BM-S (n=5). Both BAFF and APRIL
mRNA were detected in all BM microenvironment cell types
tested, but not transcripts for the BAFF-system receptors
(Figure 3A). In some specimens, a smaller APRIL transcript was
observed (Figure 3A, lower band); sequencing analysis showed that
it represents a novel alternative-spliced isoform – APRIL-e, missing
exons 2 and 3, and containing an early stop codon (Figure 3B;
deposited as GenBank EF211088).
Expression of surface BAFF and APRIL on these cell
populations was assessed by flow cytometry; illustrative cases are
shown in Figure 3C and the overall data summarized in Figure 3D.
BAFF is expressed on most of these cells, particularly on BM-EC
(mean expression 68.01%; range 32.7–92.7%). In contrast, with
exception of 1 donor, expression of surface APRIL was low to
undetectable (mean expression 9.8%; range 0.6–62.2%), which
may be due to the lack of APRIL-d transcripts. Finally, ELISA
analyses showed the presence of soluble BAFF in conditioned
medium (CM) from BM-EC cultures (Figure 3E; range: 90–
240ng/mL). Taken together, the expression pattern of BAFF-
system ligands and receptors on leukemia B-cells and BM
microenvironment cells raises the hypothesis that signals involving
this molecular axis may occur through both homotypic and
heterotypic mechanisms.
BAFF and APRIL Bind to Leukemia B-Cells Expressing
BAFF-System Receptors
To investigate whether the BAFF-system receptors expressed on
B-ALL cells are functional, we first performed binding assays on
primary B-ALL cells (n=12) using human BAFF-myc or APRIL-
flag fusion proteins. It was previously demonstrated that these
fusion proteins specifically bind to BCMA, TACI and/or BAFF-
R.[7,34,35] Figure 4A depicts three representative cases, showing
variable levels of BAFF-myc or APRIL-flag binding to primary
leukemia cells. In most patients studied, BAFF-myc binds to at
least 25% of the leukemia cells (Figure 4B; mean 31.1%, range
0.8–92.9%), whereas binding of recombinant APRIL seems to be
less pronounced (Figure 4B; mean 15.76%, range 0.8–55.3%).
BAFF Ligation to B-ALL Engages NF-kB, MAPK, and PI3K/
AKT Signaling Pathways
To demonstrate the functional integrity of BAFF-system
receptors in B-ALL cells, we evaluated whether their ligation
triggered the activation of NF-kB, MAPK, and PI3K/Akt
signaling, which are critical events on survival and proliferation
of malignant B-cells.[36,37,38] Since BAFF-R was the most
frequently expressed receptor (Figure 1), the ensuing studies were
performed using BAFF. Primary B-ALL cells (n=3) were
stimulated with BAFF-myc for different periods (5–30 minutes),
and were analyzed by immunoblotting for activation status of
IKKa/b, IKBa, p105, ERK1/2, JNK/SAPK and Akt. BAFF
ligation triggered NF-kB signaling in leukemia B-cells, as shown by
the phosphorylation of the catalytic subunits IKKa/IKKb, the
inhibitory protein IKBa, and the transcription factor p105/NF-
kB1 (Figure 5A), and subsequent augmentation of p50. BAFF
ligation to B-ALL cells also triggered the activation of MAPK
signaling, with the phosphorylation of ERK1/2 and JNK/SAPK
kinases (Figure 5B), as well as PI3K/Akt signaling, with
phosphorylation of Akt (Figure 5C). These observations demon-
strate that primary B-ALL cells express functional BAFF-system
receptors, whose ligation effectively triggers the activation of
critical signaling transduction cascades.
BAFF Potentiates Mitogenic Stimuli to B-Cell ALL
To evaluate the impact of BAFF stimulation on B-ALL
functions, primary B-ALL (n=10) were cultured for 72 h in
control medium or in the presence of BAFF-myc and/or CD40L,
as we and others have reported that CD40 ligation is mitogenic for
B-ALL cells.[39,40] BAFF alone did not promote substantial cell
proliferation (Figure 6A; mean 1.34, range 1.0–1.59-fold increase)
whereas, as expected, CD40L was mitogenic for B-ALL cells in
most cases (Figure 6A; mean 3.26, range 1.19–5.54-fold increase).
Importantly, BAFF significantly potentiated the mitogenic effect of
CD40L, with 4.84-fold increase in cell proliferation in comparison
to BAFF alone (Figure 6A; mean 6.48, range 2.06–10.76;
p=0.002 vs. BAFF alone; p=0.002 vs. CD40L alone). These
results indicate that B-ALL cells are functionally responsive to
signals through BAFF-system receptors, and that BAFF potentiates
the proliferative response of leukemia B-cells to mitogenic stimuli,
such as CD40 crosslinking.
BAFF Potentiates B-ALL Cell Survival
To assess BAFF role on B-ALL cell survival, primary B-ALL
samples (n=8) were cultured for 24h in control medium or in the
presence of BAFF-myc and/or CD40L. BAFF alone improved
ALL cell survival (Figure 6B, mean 62.51%, range 29.67–110.3%;
p=0.0078 vs. control); as expected, CD40L stimulation increased
leukemia cell viability in comparison to control conditions
(Figure 6B, mean 69.57%, range 33.6–114.0%; p=0.0078 vs.
control), without significant differences between these two
conditions (Figure 6B, p=0.1484). Interestingly, BAFF seems to
potentiate the survival effect of CD40L in comparison with
CD40L alone (Figure 6B, mean 79.22%, range 37.21–140.6%,
p=0.0156 vs. CD40L alone). Using a soluble BCMA-Fc fusion
protein with high-affinity for BAFF and APRIL, preventing their
ligation to their cognate receptors on target cells,[41] we observed
that BCMA-Fc inhibits or abrogates the survival effects of BAFF in
leukemia B-ALL cells (Figure S2).
Basal B-cell ALL Proliferation Involves Homotypic BAFF-
System Signals
Since leukemia cells also express BAFF and to a lesser extent
APRIL, we evaluated whether homotypic or autocrine mecha-
nism(s) involving these molecules may operate in B-cell ALL.
Functional studies using the soluble BCMA-Fc fusion protein,[41]
showed marked inhibition of the ‘basal’ proliferation of primary B-
ALL cells (n=10), in all cases tested (Figure 6C; mean 62.03%,
range 33.73–78.58%; p,0.0001 BCMA-Fc vs. control Fc). This
study suggests the involvement of BAFF-system ligands expressed
or secreted by leukemia B-cells in homotypic interactions and/or
autocrine loops mediating B-ALL cell functions.
Discussion
There is increasing interest in dissecting the microenvironmen-
tal cues that critically impact leukemia cell functions in the
malignant BM. We observed that leukemia precursor B-cells
aberrantly express BAFF-system receptors, and that their cognate
ligands BAFF and APRIL are expressed in the BM microenvi-
BAFF-System in B-Cell ALL
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20787Figure 3. BAFF and APRIL expression in BM microenvironmental cells. (A) Electrophoretic analysis of RT-PCR products of BAFF and APRIL in
BM-S, BM-EC and MSC. Monocytes and splenic mature B-cells used as positive controls (+) for BAFF-system ligands and receptors, respectively; PBGD
as control transcript. (B) Comparison of aminoacid sequence of APRIL-a and APRIL-e, lacking residues as dashed lines), which results from alternative
splicing with exon-1/exon-4 fusion; predicted 90 aminoacid protein lacking the furin convertase motif (in bold) and with early stop codon. (C) Flow
cytometry of BAFF, APRIL expression in representative BM-S, MSC and BM-EC cases. (D) Summary of BAFF (D) and APRIL () surface expression (%) in
BM microenvironmental cells (n=14; symbols: BM-S, open; MSC, gray; BM-EC, black). Solid line indicates mean surface expression (% of cells), as
assessed by flow cytometry. (E) ELISA for soluble BAFF in CM from BM-EC cultures (n=5 biological replicates).
doi:10.1371/journal.pone.0020787.g003
BAFF-System in B-Cell ALL
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expression of BAFF-R in B-ALL cells and showed that BAFF
stimulation supported the survival of leukemia cells, attenuating
the cytotoxic effects of the kinase inhibitor nilotinib in Ph-positive
leukemias.[42] Our work on a larger dataset of patients shows that
in addition to functional BAFF-R, B-ALL cells also express TACI
and BCMA, and that virtually all patients express at least one of
the BAFF-system receptors. More importantly, we show increased
BAFF levels in the leukemic BM, and provide evidence supporting
the involvement of both homotypic and heterotypic signals
through BAFF-system receptors in mediating B-ALL survival.
Finally, we demonstrate that blockade of these signals using a
BCMA-Fc decoy markedly inhibit or abrogate the effects of BAFF
signals in B-ALL cell survival.
The expression of functional BAFF-system receptors by B-ALL
was unexpected since their physiological expression seemed
restricted to later B-cell lineage developmental stages.[28] We
confirmed the lack of BCMA, TACI and BAFF-R proteins in
normal BCP despite detection of their respective transcripts,
suggesting post-transcriptional regulation of receptor expression in
early B-cell development. BCMA protein is seen mainly in mature
B-cells, whereas TACI and BAFF-R are first detected on
immature B-cells.[28] In humans, BAFF-R is expressed first in
immature B-cells, and BCMA and TACI in germinal center B-
cells; other study reported that, in the BM, plasma cells express
BCMA and TACI, but not BAFF-R.[43] Studies in mice null for
individual BAFF-system receptors suggest that they lack significant
physiological roles in early B-cell development.[8] The adminis-
tration of BCMA-Ig (as decoy receptor) resulted in marked
reduction of B-cells in all secondary lymphoid organs,[15]
suggesting that while BCMA is dispensable, its ligands are critical
for B-cell survival and maintenance. TACI-deficient mice
displayed elevated B-cell numbers, suggesting a role as negative
regulator of B-cell homeostasis.[24,25] The phenotype of BAFF-
R-deficient mice was similar to that of BAFF-null mice, suggesting
that the BAFF-R-BAFF axis is the main driver for B-cell survival
and maturation.[20,21,28]
Our data suggests that the malignant transformation of BCP
results in the deregulation of mechanism(s) mediating the post-
transcriptional control of BAFF-system receptor expression; it is
unknown whether this deregulation is driven by genetic or
epigenetic factors associated with BCP transformation or is a
response to microenvironment cues in the leukemic BM. BAFF-R
can be positively regulated by B-cell receptor stimulation and Toll-
like receptor (TLR)-associated signaling, and negatively regulated
by TNFR-associated factor-3; TLR signals also upregulate
TACI.[44,45,46] Although TLR mRNAs (TLR1 to -7) were
detected in leukemia lines and TLR9 protein in primary B-ALL,
and B-ALL are responsive to TLR stimulation by CpG
oligodeoxynucleotides,[47,48] there is no evidence supporting a
role for TLR signals within the leukemic BM, or their effects in B-
ALL biology.
Previous studies identified the malignant microenvironment as
the main source of BAFF-system ligands in BM cancers. In
myeloma, it has been shown BAFF/APRIL secretion by
monocytes, neutrophils, and osteoclasts (only APRIL), but not by
stromal cells;[49] other study showed BAFF surface expression and
increased levels of soluble BAFF and APRIL in supernatants of
patient-derived stroma in comparison to stromal cells from normal
donors.[50] In CLL, leukemia-supporting nurse-like cells express
high BAFF and APRIL levels, which seem to mediate leukemia
cell survival.[38] Our observation that BM-EC express and secrete
BAFF is interesting, as studies suggest an important role for BM
endothelial niches on leukemia cell survival[6,33], and for the
regulation of normal, and possibly, leukemia stem cells. It would
be interesting to investigate whether BAFF-/APRIL-rich areas in
the BM (as seen for plasma B-cells),[51] are involved in regulating
B-ALL cells with leukemia-initiating properties. The expression of
BAFF/APRIL by leukemia BCP suggests the involvement of
BAFF-system signaling, via cell-cell contact and/or through
autocrine mechanisms. BAFF and APRIL expression was reported
in other B-cell malignancies, namely non-Hodgkin’s lymphoma,
plasma-cell leukemia and Waldenstrom’s macroglobuline-
mia;[8,31,51] APRIL as a soluble factor, whereas BAFF was
detected both as soluble and membrane form.[8] Here, we
identified a new APRIL isoform, APRIL-d, lacking the consensus
motif for furin convertase-mediated cleavage,[32] which may
explain the surface APRIL seen in B-ALL cells. Analyses of
genomic sequences (introns 1–2) showed canonical splicing donor
and acceptor sites in the human gene and in other species (Figure
S3). In addition to soluble BAFF, which is elevated in patients’
plasma, leukemia B-cells express membrane BAFF and blockade
with BCMA-Fc markedly inhibited basal leukemia cell prolifera-
tion, further supporting the involvement of homotypic interactions
on the functional role of the BAFF-system in B-ALL.
Figure 4. BAFF and APRIL bind to primary B-ALL cells. (A) Flow
cytometry analyses of BAFF and APRIL binding to primary B-ALL cells,
on three representative patients. (B) Summary of BAFF (F) and APRIL (x)
binding to primary B-ALL cells (n=12); solid line represents the mean
binding of the respective ligands (% of cells), as assessed by flow
cytometry.
doi:10.1371/journal.pone.0020787.g004
BAFF-System in B-Cell ALL
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20787The B-ALL-expressed BAFF-system receptors are functional as
they bind BAFF and/or APRIL and their ligation triggers NF-kB,
MAPK, and Akt signaling, mediating leukemia cell survival and
potentiating their response to CD40L mitogenic signals. NF-kB
and MAPK activation was expected, and sheds light on molecular
mechanisms by which BM microenvironmental cues, or at least
extrinsic signals, may impact on leukemia BCP. Studies in other B-
cell malignancies (lymphoma, myeloma and CLL) showed the
engagement of NF-kB, MAPK, and Akt by BAFF or APRIL
stimulation.[36,37,38] Our study unveils the involvement of new
molecular axis in the biology of malignant BCP, particularly in the
crosstalk between leukemia cells and their supportive BM
microenvironment.
We observed BAFF-system spliced isoforms in B-ALL cells,
including a TACI isoform (GenBank AY302137), APRIL-b
(NM_172087), APRIL-c (NM_172088), and the newly identified
APRIL-d and APRIL-e (GenBank DQ149579 and EF211088,
respectively). APRIL-e was also seen in microenvironmental cells. It
is unknown if these isoforms are translated into functional proteins,
and whether they may trigger signals on leukemia B-cells or alter
their responsiveness to BAFF/APRIL signals (such as decoy
receptors). We observed that a novel BCMA isoform is secreted as
a soluble receptor that effectively inhibits BAFF signals in mature
B-cells (Maia et al., manuscript submitted), but have no evidence
that it may affect the effects of BAFF/APRIL on leukemia cells
within the BM microenvironment.
Figure 5. BAFF activates NF-kB, MAPK, and Akt signaling in primary B-ALL. (A) BAFF-triggered NF-kB activation was assessed by
immunoblotting using antibodies for p-IKKa/p-IKKb, p-IkBa, p-p105, the precursor form of p105 and its activated form p50. (B) MAPK activation by
assessing the phosphorylation status of ERK1/2 and SAPK/JNK. (C) PI3K/Akt activation assessed using antibody for p-Akt.
doi:10.1371/journal.pone.0020787.g005
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offers new and unanticipated molecular target(s) for this
cancer. Several therapeutic agents (as the anti-BAFF antibody
Lymphostat-B, the BAFF-antagonist AMG-623, and decoy
fusion proteins TACI-Fc/Atacicept, BCMA-Fc, BR3-Fc) are
being assessed for the targeted disruption of the BAFF-system
in B-cell disorders and hematological malignancies.[8,31]
Studies are necessary to define the critical role of BAFF-
system-triggered signals in B-ALL development, and to validate
BAFF-system targeting as a valid strategy for the treatment of B-
ALL patients.
Materials and Methods
Ethics Statement
Appropriate written informed consent was obtained and studies
performed in accordance with the Declaration of Helsinki, and
under a protocol approved by the Dana-Farber Cancer Institute’s
Institutional Review Board.
Primary Cells and Cell Lines
Leukemia or normal specimens were collected according to
institutional guidelines. B-ALL cells (diagnostic; .90% blasts)
were collected from patients’ BM or peripheral blood (PB) and
included 21 BM, 22 PB and 6 BM+PB samples; mononuclear cells
(MNC) were isolated by density centrifugation, and used for
phenotypic, signaling and functional studies. Normal B-cell
precursors (BCP; CD19
+Igk
-/Igl
-) were selected from BM of 4
age-matched healthy donors using fluorescence-activated-cell-
sorting (Coulter EpicsALTRA). BM microenvironmental cells
(BM-EC; MSC; BM-S) were isolated from healthy donor’s BM
aspirates: BM-EC were purified using CD105 microbeads
(Miltenyi-Biotech, Auburn, CA), and selected by culturing in
EGM-2 (containing bFGF, VEGF, EGF and IGF-1; Cambrex,
Figure 6. BAFF potentiates proliferation and mediates survival of primary B-ALL cells. (A) Proliferation of primary B-ALL cells (n=10)
cultured in medium alone (Control, x), BAFF-myc (%), CD40L () or BAFF-myc+CD40L (#), as measured by thymidine incorporation. Each point
corresponds to mean stimulation index (i.e, proliferation of test condition divided by proliferation in control medium) for each patient tested, per
condition; solid line indicates the mean stimulation index per experimental condition. Statistical analysis performed using the Wilcoxon test. (B)
Primary B-ALL (n=8) cultured in control medium (D) or with BAFF-myc (%), CD40L () or BAFF-myc+CD40L (#), and evaluated for cellular viability.
Each point corresponds to mean survival percentage for each patient tested, per condition; solid lines indicate mean survival percentage per
experimental condition. Statistical analysis performed using the Wilcoxon test. (C) Primary B-ALL cells (n=10) cultured with BCMA-Fc (black bars) or
control fusion protein (white bars). Experiments performed in triplicate, and results expressed as mean proliferation index (i.e, proliferation in BCMA-
Fc divided by proliferation in control-Fc) for BCMA-Fc vs. control fusion protein.
doi:10.1371/journal.pone.0020787.g006
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+ fraction
and selected by culture in MSCGM (Cambrex); BM-S cells
prepared from the adherent fraction of MNC, through culture in
MyeloCult
TM media (Stem Cell Technologies, Vancouver,
Canada), and were mainly composed of myofibroblasts. B-ALL
cell lines 207, REH, SUP-B15, NALM-6 and RS4;11 were
obtained from ATCC (Manassas, VA) or DSZM (Braunschweig,
Germany), and BLIN-1 from Dr. Tucker LeBien (Univ.
Minnesota); cells were tested prior use by flow cytometry to
confirm their phenotype and developmental stage. Leukemia cells
(lines, patients) were cultured in RPMI supplemented with 10%
FBS (hereafter referred as RPMI-FBS).
RT-PCR and Sequencing
Total RNA was purified using TRIZOL (Invitrogen, Carlsbad,
CA), and cDNA prepared by reverse transcription at 42uCi na
mix containing Improm II (Promega, Madison, WI) and pd(N)
hexamers (Amersham). PCR amplifications of BCMA, TACI,
BAFF-R, APRIL and BAFF were performed as described in Table
S2. Amplification of the housekeeping gene PBGD was used as
control. Specific bands were extracted, purified (QIAquick kit,
Qiagen, Valencia, CA), and analyzed in an automatic sequencer
(Applied Biosystems, Foster City, CA).
Flow Cytometry Analyses
After Fc receptor blockade, cells were incubated with antibodies
for: BCMA (R&D, Minneapolis, MN), BAFF (eBioscience,
SanDiego, CA), TACI, BAFF-R or APRIL (Biogen Idec, Cam-
bridge, MA), followed by fluorochrome-labeled secondary anti-
bodies (Southern Biotechnology, Birmingham, AL). In B-ALL
cells, CD19 was used as a B-cell marker (Beckman-Coulter,
Miami, FL). As control, appropriate irrelevant isotype-matched
antibodies were used. Cells were analyzed using a Cytomics
TM
FC500 cytometer (Beckman-Coulter) (at least 20,000-gated events
acquired); data was analyzed using FlowJo (Tree Star, Ashland,
OR).
BAFF and APRIL Binding Assay
B-ALL cells were incubated with BAFF-myc or APRIL-flag
fusion proteins (Biogen), washed, incubated with anti-myc (Santa
Cruz Biotechnology, Santa Cruz, CA) or anti-flag M2 (Sigma, St.
Louis, MO) antibodies, respectively, followed by goat-anti-mouse
Ig-RPE antibodies. An irrelevant human Fc fusion protein was
used as control. Samples were acquired using Cytomics
TM FC500
and analyzed using FlowJo.
Proliferation and Viability Assays
Viable primary B-ALL cells were cultured in RPMI-FBS
(2610
6/mL) in 96-well plates for 72 h, in the presence of sCD40L
(500 ng/mL; PeproTech, NJ), BAFF-myc (100 ng/mL; Biogen),
BCMA-Fc (10 mg/mL; R&D), or control irrelevant fusion
proteins, in the conditions indicated. Tritiated-thymidine (1 mCi/
well) was added for 18 h prior to cell harvest, and thymidine
incorporation determined using a Wallac Microbeta counter
(Wallac-Oy, Turku, Finland). All conditions were tested in
triplicate.
For viability assay, primary B-ALL cells were cultured in RPMI-
FBS (223610
5 cells/well) in 96-well plates for 24 h, in the
presence of sCD40L (500 ng/mL; PeproTech), BAFF-myc
(100 ng/mL; Biogen), BCMA-Fc (10 mg/mL; R&D), or control
irrelevant fusion proteins, in the conditions indicated. CellTiter-
Glo luminescent cell viability assay (Promega, Madison, WI) was
used. All conditions were tested in triplicate.
Immunoblotting
Primary B-ALL cells were stimulated with BAFF-flag (100 ng/
mL; Biogen) for the periods indicated, and lysates prepared in
RIPA buffer. Immunoblotting was performed using antibodies for:
p-IKKa(Ser180)/IKKb(Ser181), p-IkBa(Ser32), p-p105(Ser933),
p105, p-AKT(Ser473), p-JNK/SAPK(Thr183/Tyr185) (Cell Sig-
naling, Danvers, MA); p-ERK1/2(Tyr204) (Santa Cruz); Actin
(Sigma); and HRP-conjugated secondary antibodies (Promega).
BAFF Quantification
Plasma from B-ALL patients and age-matched healthy donors
was collected at diagnosis. After specimen centrifugation were
filtered and kept at –70uC. Plasmas were diluted (1:10) in PBS-
1%BSA and precleared using protein A–Sepharose beads (10%v/
v; Amersham). For conditioned media (CM) preparation, BM-EC
were cultured to sub-confluence in EGM2. After washing with
PBS, cells were cultured in serum/cytokine-free EBM2 media
with, 0.5% BSA. CM were collected after 72 h, filtered and used
immediately or stored at 270uC.
BAFF quantification was performed by ELISA with anti-BAFF
capture and detection antibodies. Briefly, ELISA plates were coated
overnight with anti-BAFF Buffy-5 antibody (2 mg/mL; Biogen);
after blocking, serial dilutions of precleared sera were added,
followed by a biotin-conjugated mouse-anti-human BAFF (0.5 mg/
mL; Biogen). Detection was performed using alkaline phosphatase-
conjugated streptavidin (Jackson ImmunoResearch) and appropri-
ate substrate (Sigma). Plates were read at 405 nm, with standard
curves generated using known quantities of rhBAFF, diluted in
human serum and treated as described above for patients’ samples.
Statistical Analysis
Statistical significance was determined using the two-tailed non-
parametric Mann-Whitney and Wilcoxon tests, using the Graph-
pad Prism-4.0 software (GraphPad, San Diego, CA). Differences
were considered statistically significant when p#0.05.
Supporting Information
Figure S1 Sequence alignment of human APRIL-a and
APRIL-d proteins. The accession numbers of the sequences on
the NCBI database are shown; NP_003799.1 corresponds to
APRIL-a protein, and the ABA39072.1 sequence corresponds to
the predicted APRIL-d protein encoded by the exon-2-lacking
spliced isoform identified in our B-ALL samples (DQ149579.1).
The sequence NP_001185551.1 corresponds to the APRIL variant
delta recently deposited by the DREAM investigators (mRNA
accession number NM_001198622.1). The yellow box indicates the
furin convertase motif RKRR, involved in the proteolytic cleavage
of APRIL. Sequence analyses and alignments were performed using
the ClustalW2 algorithm, for multiple sequence alignment [Chenna
R, Sugawara H, Koike T, Lopez R, Gibson TJ, et al. (2003)
Multiple sequence alignment with the Clustal series of programs.
Nucleic Acids Res 31: 3497–3500.]. Below the alignment, a
consensus line indicates: identical residues in all sequences (*).
(DOC)
Figure S2 BCMA-Fc inhibits or abrogates the survival
effect of BAFF on primary B-ALL cells. Leukemia cells
(n=3) were cultured in control medium (white bars), with BAFF-
myc (100 ng/mL; gray bars) or with BAFF-myc (100 ng/mL) plus
BCMA-Fc (10 mg/mL; black bars). ATP levels were quantified at
24 h and results expressed as mean Survival Index, compared to
cell viability measured at day 0 (set as 100%).
(DOC)
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showing the exonic-intronic boundaries (exon 1 to exon
3). Nucleotides of exons are show in red, whereas intronic
sequences are shown in black. The splicing sites donor GT and
acceptor AG are indicated by the yellow or green boxes,
respectively. Species abbreviations: Hs, Homo sapiens; Mm, Mus
musculus. Rn, Rattus norvegicus; Bt, Bos taurus. Sequences were
collected from the NCBI database, and the respective accession
numbers are indicated.
(DOC)
Table S1 Clinical characteristics of B-cell ALL patients
(n=72) used in this study. Abbreviations: #, number; WBC,
white blood cell count.
(DOC)
Table S2 Oligonucleotides and PCR conditions used for
the amplification of BCMA, TACI, BAFF-R, APRIL, BAFF
and PBGD.
(DOC)
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